Ani Pharmaceuticals Inc ANIP
We take great care to ensure that the data presented and summarized in this overview for ANI PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANIP
View all-
Black Rock Inc. New York, NY2.66MShares$154 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.31MShares$76.2 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1MShares$58.1 Million0.03% of portfolio
-
State Street Corp Boston, MA737KShares$42.7 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY700KShares$40.5 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX686KShares$39.7 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT649KShares$37.6 Million1.58% of portfolio
-
Global Alpha Capital Management Ltd.625KShares$36.2 Million2.5% of portfolio
-
Ubs Group Ag595KShares$34.5 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il592KShares$34.3 Million0.01% of portfolio
Latest Institutional Activity in ANIP
Top Purchases
Top Sells
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Insider Transactions at ANIP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 21
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-1.44%
|
$60,000
$60.2 P/Share
|
|
Feb 15
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-1.15%
|
$67,686
$58.92 P/Share
|
|
Feb 15
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,184
-1.02%
|
$68,672
$58.92 P/Share
|
|
Feb 14
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,426
-1.38%
|
$82,708
$58.92 P/Share
|
|
Feb 14
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,799
-1.49%
|
$452,342
$58.92 P/Share
|
|
Feb 14
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,473
-1.25%
|
$85,434
$58.92 P/Share
|
|
Feb 14
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
SELL
Payment of exercise price or tax liability
|
Direct |
582
-1.25%
|
$33,756
$58.92 P/Share
|
|
Feb 14
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,730
-0.88%
|
$100,340
$58.92 P/Share
|
|
Feb 14
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,434
-1.72%
|
$83,172
$58.92 P/Share
|
|
Feb 14
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,196
-1.69%
|
$69,368
$58.92 P/Share
|
|
Feb 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.48%
|
$23,600
$59.54 P/Share
|
|
Feb 12
2025
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Grant, award, or other acquisition
|
Direct |
23,936
+12.06%
|
-
|
|
Feb 12
2025
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
26,112
+11.81%
|
-
|
|
Feb 12
2025
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
152,331
+13.48%
|
-
|
|
Feb 12
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
41,346
+15.95%
|
-
|
|
Feb 12
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
BUY
Grant, award, or other acquisition
|
Direct |
13,056
+12.98%
|
-
|
|
Feb 12
2025
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
41,346
+9.97%
|
-
|
|
Feb 12
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
28,290
+15.42%
|
-
|
|
Feb 12
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,761
+14.16%
|
-
|
|
Feb 12
2025
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Grant, award, or other acquisition
|
Direct |
23,936
+14.91%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 399K shares |
|---|---|
| Exercise of conversion of derivative security | 42.6K shares |
| Payment of exercise price or tax liability | 120K shares |
|---|---|
| Open market or private sale | 521K shares |